AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10483927 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic sleep deprivation (TSD) + paroxetine
Number of subjects: 173
Study 10483927 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 173
Study 10483927 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 173
Study 10483927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% dorzolamide
Number of subjects: 333
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% dorzolamide
Number of subjects: 333
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% dorzolamide
Number of subjects: 333
Study 8694086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle of dorzolamide)
Number of subjects: 333
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% dorzolamide (one-year extension)
Number of subjects: 333
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% dorzolamide (one-year extension)
Number of subjects: 333
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol (if needed during one-year extension)
Number of subjects: 333
Study 8694086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide (after 12 months)
Number of subjects: 333
Study 1831628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (ondansetron 0.15 mg/kg IV every 2 hours + dexamethasone 20 mg IV single dose)
Number of subjects: 0
Study 1831628 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone (ondansetron 0.15 mg/kg IV every 2 hours)
Number of subjects: 0
Study 6807081 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 17
Study 31750145 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporalis fascia
Number of subjects: 40
Study 31750145 — intervention group
Group type: EXPERIMENTAL
Intervention: Conchal cartilage
Number of subjects: 40
Study 28757439 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic simulator assessment metrics (dV‐Trainer and da Vinci Skills Simulator)
Number of subjects: 74
Study 28757439 — intervention group
Group type: COMPARATOR
Intervention: GEARS evaluation scores
Number of subjects: 74
Study 25649640 — intervention group
Group type: EXPERIMENTAL
Intervention: Avizor Alvera® (study solution)
Number of subjects: 20
Study 25649640 — intervention group
Group type: COMPARATOR
Intervention: All Clean Soft® (control solution)
Number of subjects: 20
Study 24819510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) along with physical measures (compression stockings)
Number of subjects: 74
Study 24819510 — intervention group
Group type: COMPARATOR
Intervention: Physical measures (compression stockings) only
Number of subjects: 74
Study 21849647 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β‐1b (250 μg, subcutaneously every other day for 2 years)
Number of subjects: 292
Study 19139851 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone 6 mg/day
Number of subjects: 78
Study 19139851 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol 20 mg/day
Number of subjects: 78
Study 19139851 — intervention group
Group type: COMPARATOR
Intervention: Medication-free SCH patients
Number of subjects: 78
Study 17456248 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin tablets (n 28)
Number of subjects: 55
Study 17456248 — intervention group
Group type: COMPARATOR
Intervention: Fish oil capsules (n 27)
Number of subjects: 55
Study 12841346 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (120 mg/day)
Number of subjects: 144
Study 12841346 — intervention group
Group type: COMPARATOR
Intervention: Control (B vitamin group B)
Number of subjects: 144
Study 10543679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential transdermal progesterone with continuous transdermal oestrogen
Number of subjects: 0
Study 9345379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 0
Study 9345379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1861000 — intervention group
Group type: EXPERIMENTAL
Intervention: I tones with periods close to p (± 3% or 6% apart)
Number of subjects: 0
Study 1861000 — intervention group
Group type: EXPERIMENTAL
Intervention: I tones with same harmonic content as the test tones
Number of subjects: 0
Study 1861000 — intervention group
Group type: EXPERIMENTAL
Intervention: I tones with very different harmonic content
Number of subjects: 0
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy (4000 rads) and elective radical cystectomy
Number of subjects: 189
Study 7044462 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (4000 rads plus 2000 rads boost)
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy and cystectomy in patients aged less than 60
Number of subjects: 189
Study 7044462 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy in patients aged less than 60
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy and cystectomy in males
Number of subjects: 189
Study 7044462 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy in males
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cystectomy when lymph nodes are not involved
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cystectomy when lymph nodes are positive
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage cystectomy for local tumour recurrence following radical radiotherapy
Number of subjects: 189
Study 7044462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pelvic metastases
Number of subjects: 189
Study 31027120 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal bupivacaine injection
Number of subjects: 86
Study 31027120 — intervention group
Group type: COMPARATOR
Intervention: Conventional solution
Number of subjects: 86
Study 27779568 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (o‐CEE) 0.45 mg (n=230)
Number of subjects: 727
Study 27779568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (t‐E2) 50 μg (n=225)
Number of subjects: 727
Study 27779568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) (n=275)
Number of subjects: 727
Study 26720504 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 2148
Study 26720504 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2148
Study 22692123 — intervention group
Group type: EXPERIMENTAL
Intervention: HImax (1 set of 10-12 repetitions at 80% 1RM)
Number of subjects: 36
Study 22692123 — intervention group
Group type: EXPERIMENTAL
Intervention: LOmax (1 set of 10-12 repetitions at 40% 1RM, preceded by 60 repetitions at 20-25% 1RM)
Number of subjects: 36
Study 22692123 — intervention group
Group type: COMPARATOR
Intervention: LO (1 set of 10-12 repetitions at 40% 1RM, no maximal effort)
Number of subjects: 36
Study 21448726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch-double tract (PDT)
Number of subjects: 29
Study 21448726 — intervention group
Group type: COMPARATOR
Intervention: Conventional Roux-en-Y reconstruction (RY)
Number of subjects: 29
Study 19195512 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg orally twice daily)
Number of subjects: 205
Study 19195512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 19195512 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 205
Study 17035452 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-related symptoms assessed using the CAP score
Number of subjects: 102
Study 17035452 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQL assessed using the SF-36 questionnaire at 18 months
Number of subjects: 102
Study 15190700 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric model of compressed individual color spaces
Number of subjects: 0
Study 15190700 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 10353511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg (single intramuscular dose)
Number of subjects: 513
Study 10353511 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate, 80 mg/kg/day of amoxicillin: 10 mg/kg/day of clavulanate for 10 days
Number of subjects: 513
Study 10353511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 513
Study 10353511 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 513
Study 8599787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (intramuscularly)
Number of subjects: 52
Study 8599787 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (rectally)
Number of subjects: 52
Study 8599787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1770473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lipid-lowering and antihypertensive treatment
Number of subjects: 36
Study 1770473 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study 7054311 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride pretreatment
Number of subjects: 0
Study 30155904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection advice and equipment
Number of subjects: 98
Study 30155904 — intervention group
Group type: COMPARATOR
Intervention: No sun protection advice and equipment (Control)
Number of subjects: 98
Study 29222893 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (KO) - 5 capsules (907 mg LC n-3 PUFA)
Number of subjects: 10
Study 29222893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) - 5 capsules (1441 mg LC n-3 PUFA)
Number of subjects: 10
Study 29222893 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) - control
Number of subjects: 10
Study 26366639 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated symptoms of depression (BDI‐II)
Number of subjects: 132
Study 26366639 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated symptoms of distress (GHQ)
Number of subjects: 132
Study 26366639 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety (Spielberger Anxiety Inventory)
Number of subjects: 132
Study 24523436 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) applied to the collapsed right lung
Number of subjects: 30
Study 24523436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 30
Study 24523436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPAP and Control)
Number of subjects: 30
Study 22444237 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate treatment (PCT) - 600 ml of a carbohydrate-based drink (ONS, Fresenuis Kabi, 50 g carbohydrate, 15 g glutamine and antioxidants/300 ml)
Number of subjects: 30
Study 22444237 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 600 ml of a carbohydrate-free drink (0 g carbohydrate)
Number of subjects: 30
Study 20609131 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg IV-ibuprofen every 6 hours
Number of subjects: 185
Study 20609131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 17907107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 0.25 mg
Number of subjects: 222
Study 17907107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 0.5 mg
Number of subjects: 222
Study 17907107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg
Number of subjects: 222
Study 17907107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar (all doses)
Number of subjects: 222
Study 16045858 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 30
Study 16045858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 30
Study 16045858 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 16045858 — intervention group
Group type: COMPARATOR
Intervention: ACTH stimulation test
Number of subjects: 30
Study 12239480 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkmax (self-etching adhesive and its respective cement)
Number of subjects: 22
Study 12239480 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC (conventionally etched adhesive and its cement)
Number of subjects: 22
Study 12239480 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 22
Study 10570375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel pretreatment 3 times per week for 2 weeks
Number of subjects: 0
Study 10570375 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin application of tazarotene gel immediately before phototherapy
Number of subjects: 0
Study 10570375 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick application of tazarotene gel immediately before phototherapy
Number of subjects: 0
Study 8635058 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Group A)
Number of subjects: 66
Study 8635058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (Group B)
Number of subjects: 66
Study 2127226 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (400 mg)
Number of subjects: 8
Study 2127226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30841930 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (self-applied)
Number of subjects: 69
Study 30841930 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (with therapist guidance)
Number of subjects: 69
Study 30841930 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 69
Study 30841930 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (both methods)
Number of subjects: 69
Study 28152673 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-overload training (EOT)
Number of subjects: 18
Study 28152673 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 25177768 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ureterolithotomy (LU)
Number of subjects: 110
Study 25177768 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopic lithotripsy (URS)
Number of subjects: 110
Study 23530969 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 (20 mg/kg per day)
Number of subjects: 21
Study 23530969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22085316 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg daily
Number of subjects: 1039
Study 22085316 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin, 40 mg daily
Number of subjects: 1039
Study 19088267 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 487 at 25 mg
Number of subjects: 0
Study 19088267 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 487 at higher doses (not specified)
Number of subjects: 0
Study 19088267 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 487
Number of subjects: 0
Study 19088267 — intervention group
Group type: EXPERIMENTAL
Intervention: M2 (metabolite of AMG 487)
Number of subjects: 0
Study 19088267 — intervention group
Group type: EXPERIMENTAL
Intervention: M2
Number of subjects: 0
Study 18193495 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard gel applied vaginally once per day for 14 days (women)
Number of subjects: 60
Study 18193495 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard gel applied directly to the penis once per day for 7 days (men)
Number of subjects: 60
Study 18193495 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose placebo
Number of subjects: 60
Study 18193495 — intervention group
Group type: COMPARATOR
Intervention: No product (control)
Number of subjects: 60
Study 15586635 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in NC
Number of subjects: 16
Study 15586635 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in PD
Number of subjects: 16
Study 15586635 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in NC with subdivided ROI
Number of subjects: 16
Study 15586635 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in PD with subdivided ROI
Number of subjects: 16
Study 11528360 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavones (approximately 50 mg)
Number of subjects: 30
Study 11528360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9779530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 80
Study 9779530 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 80
Study 7522899 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplantation of CD34-positive cells
Number of subjects: 66
Study 7522899 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrichment of CD34+ cells from PBPC collections
Number of subjects: 66
Study 2901993 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine (BW 825C; 8 mg 3 times daily)
Number of subjects: 18
Study 2901993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (4 mg 3 times daily)
Number of subjects: 18
Study 2901993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30808264 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training interventions
Number of subjects: 0
Study 30808264 — intervention group
Group type: COMPARATOR
Intervention: Control group (preferably active)
Number of subjects: 0
Study 29715448 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical safety checklist
Number of subjects: 80
Study 29715448 — intervention group
Group type: COMPARATOR
Intervention: No checklist (Control)
Number of subjects: 80
Study 29166928 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation
Number of subjects: 1954
Study 29166928 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone (Control)
Number of subjects: 1954
Study 26600645 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Hibiscus sabdariffa (150 mg/kg/day)
Number of subjects: 78
Study 26600645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 78
Study 26600645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mg/kg/day)
Number of subjects: 78
Study 23786757 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 232
Study 23786757 — intervention group
Group type: COMPARATOR
Intervention: High Annexin A1 expression
Number of subjects: 232
Study 20096534 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + TME
Number of subjects: 1417
Study 20096534 — intervention group
Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 1417
Study 20096534 — intervention group
Group type: EXPERIMENTAL
Intervention: APR surgery
Number of subjects: 1417
Study 20096534 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative circumferential resection margin
Number of subjects: 1417
Study 20096534 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced tumors
Number of subjects: 1417
Study 20096534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral LR
Number of subjects: 1417
Study 20096534 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior or anastomotic LRs
Number of subjects: 1417
Study 17973330 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS)
Number of subjects: 0
Study 17973330 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 16644434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased preload by rapid infusion of 30 mL/kg of saline over 15 minutes
Number of subjects: 17
Study 16644434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased afterload simulated in a controlled hypoxic environment (fractional concentration of oxygen in inspired gas = 12.3%)
Number of subjects: 17
Study 12756423 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-herb interaction pairs involving herbal products and drugs
Number of subjects: 22
Study 12756423 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 22
Study 12756423 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 22
Study 11019879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tscherning aberrometer
Number of subjects: 300
Study 8701626 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/die)
Number of subjects: 40
Study 8701626 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐analogon (Decapeptyl‐Depot)
Number of subjects: 40
Study 8701626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 40
Study 1627048 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 0
Study 1627048 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 0
Study 1627048 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 6430811 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg 4 times daily)
Number of subjects: 59
Study 6430811 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (10 mg 4 times daily)
Number of subjects: 59
Study 6430811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31082447 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portions of unhealthy snacks
Number of subjects: 511
Study 31082447 — intervention group
Group type: COMPARATOR
Intervention: Small portions of unhealthy snacks
Number of subjects: 511
Study 30395548 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Right Unilateral Ultrabrief ECT (RULUB)
Number of subjects: 214
Study 30395548 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal ECT (BT)
Number of subjects: 214